Trulicity® is an injectable drug used to treat type 2 diabetes. It is part of a class of drugs commonly known as glucagon-like peptide 1 (GLP-1) agonists. Other drugs in this class include Ozempic®, Rybelsus® and Wegovy®.
Some of the common side effects of GLP-1 drugs include nausea, vomiting and diarrhea.
Unfortunately, research has suggested that GLP-1 agonists have been associated with gastroparesis—stomach paralysis where patients take far longer than normal to digest their food.
Type 2 diabetes patients who inject Trulicity® and other GLP-agonists and develop gastroparesis may experience one of more of several painful symptoms, including:
- Acid reflux
- Bloating
- Constipation
- Lost appetite
- Malnutrition
More significantly, a failure to properly and timely digest food may lead to bowel obstruction or blockage requiring hospitalization and surgery.
At Clark, Perdue & List, we are currently investigating claims involving GLP-1 agonists and gastroparesis. If you or a loved one has been prescribed a GLP-1 agonist and has experienced complications of gastroparesis, please contact us for more information.
Have questions about your legal situation?
Speaking with an experienced attorney can make all the difference. Our team is ready to listen, evaluate your case, and explain your options clearly.
📞 Call us today at (614) 469-1400 for a free, confidential consultation.
Disclaimer: The information provided in this article is for general informational purposes only and does not constitute legal advice. Every case is unique, and laws are subject to change. Reading this article does not create an attorney-client relationship. Please consult with a qualified attorney regarding your specific legal situation.
Share With Your Colleagues